Compare VOYA & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VOYA | GKOS |
|---|---|---|
| Founded | 1975 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 6.0B |
| IPO Year | N/A | 2015 |
| Metric | VOYA | GKOS |
|---|---|---|
| Price | $66.20 | $103.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 14 |
| Target Price | $85.70 | ★ $133.07 |
| AVG Volume (30 Days) | ★ 983.8K | 591.7K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.73% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $507,442,000.00 |
| Revenue This Year | $4.27 | $23.34 |
| Revenue Next Year | $4.98 | $27.46 |
| P/E Ratio | $12.00 | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $52.43 | $73.16 |
| 52 Week High | $79.99 | $130.23 |
| Indicator | VOYA | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 40.67 | 44.08 |
| Support Level | $65.17 | $94.92 |
| Resistance Level | $73.41 | $104.66 |
| Average True Range (ATR) | 1.81 | 4.03 |
| MACD | 0.25 | 0.64 |
| Stochastic Oscillator | 26.63 | 54.14 |
Voya Financial Inc is a financial services company, which, through its subsidiaries, provides various investment, insurance, and retirement solutions to individual and institutional clients in the United States. Its products and services include tax savings plans, individual retirement accounts, group life insurance plans, and employee benefits products, among others. The company tailors each of its products to the needs of its customer base. It operates its business through three principal lines: Wealth Solutions, Investment Management, and Health Solutions The Wealth segment generates roughly half of the company's revenue.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.